MGH/Harvard Study: Assessment of Glutamatergic Neurosystem in Fragile X Syndrome for Targeted Therapy
- Medical history and behavioral testing (approx. 1.5 hours)
- PET-MRI (approx. 2 hours)
- Magnetoencephalography (approx. 1 hour).
The study started on March 15, 2018, and ends by June 30, 2020. The IRB approval number is 2017P001039.
Travel/time subsidy: compensation up to $350 for participation.
If you are interested, please contact:
Maria Mody, PhD